MoonLake Immunotherapeutics(MLTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:01 AM ET (Korea 10/30 17:01)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.84 | Insider Own | 11.74% | Shs Outstand | 83.6M | Perf Week | 1.86% |
| Market Cap | 1.07B | Forward P/E | - | EPS next Y | -1.19% | Insider Trans | -4.62% | Shs Float | 75.1M | Perf Month | 7.44% |
| Enterprise Value | 0.63B | PEG | - | EPS next Q | -0.78 | Inst Own | 82.48% | Short Float | 10.43% | Perf Quarter | -31.83% |
| Income | -0.26B | P/S | - | EPS this Y | 4.44% | Inst Trans | 14.02% | Short Ratio | 4.84 | Perf Half Y | -23.26% |
| Sales | 0.00B | P/B | 2.45 | EPS next 5Y | 9.01% | ROA | -51% | Short Interest | 7.83M | Perf YTD | -4.63% |
| Book/sh | 5.12 | P/C | 1.99 | EPS past 3/5Y | -27.48% -256.78% | ROE | -67.44% | 52W High | -46.03% ($23.29) | Perf Year | 30.8% |
| Cash/sh | 6.31 | P/FCF | - | Sales past 3/5Y | - | ROIC | -49.89% | 52W Low | 34.15% ($9.37) | Perf 3Y | -74.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -37.48% | Gross Margin | - | Volatility(W/M) | 5.91% 6.57% | Perf 5Y | 25.7% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.74 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.56 | EPS Q/Q | 4.17% | Profit Margin | - | RSI (14) | 59 | Recom | 1.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.56 | Sales Q/Q | - | SMA20 | 14.02% ($11.02) | Beta | 1.13 | Target Price | $30.38 |
| Payout | - | Debt/Eq | 0.24 | Earnings | 2026/8/10 | SMA50 | -0.27% ($12.6) | Rel Volume | 2.53 | Prev Close | $12.31 |
| Employees | 130 | LT Debt/Eq | 0.23 | EPS/Sales Surpr. | 8.48% - | SMA200 | -23.78% ($16.49) | Avg Volume(3M) | 1.62M | Price | $12.57 |
| IPO | 2020/10/20 | Option/Short | Yes/Yes | Trades | 14233 | Volume | 4,097,306 | Change | 2.11% |
🧬 MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotech developing sonelokimab, a nanobody-based novel drug that simultaneously targets interleukin-17A and interleukin-17F. Its lead indications are inflammatory skin and rheumatic diseases such as hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis. The company is headquartered in Switzerland and runs a global clinical program.
Over the past 1 year, on the lower side
46% below its 1-year high.
Traded more than usual. That is 253% of its average volume.
MLTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +4.4% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +25.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 82.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #155 of 594 in the industry
Based on market cap of $1B.
IMTX#151 Immatics N.V $1B PER - 
JANX#152 Janux Therapeutics Inc $1B PER - 
SGP#153 SpyGlass Pharma Inc $1B PER - 
INBX#154 Inhibrx Biosciences Inc $1B PER - MLTX#155 MoonLake Immunotherapeutics $1B PER - 
FAQ
What kind of company is MLTX?
MLTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MLTX?
The market cap of MLTX is approximately $1.1B, ranking 2,543 within its sector.
What is the 52-week high and low for MLTX?
MLTX has recorded a 52-week high of $23.29 and a low of $9.37.
